Name of journal: *World Journal of Experimental Medicine*

ESPS Manuscript NO: 14624

Columns: REVIEW

**Spotlights on immunological effects of reactive nitrogen species: When inflammation says NO**

Predonzani A *et al.* Nitric oxide and RNS in immunity

Andrea Predonzani, Bianca Calì, Andrielly HR Agnellini, Barbara Molon

**Andrea Predonzani, Barbara Molon,** Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), 35128 Padova, Italy

**Bianca Calì, Andrielly HR Agnellini,** Venetian Institute of Molecular Medicine, 35129 Padua, Italy

**Bianca Calì,** Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy

**Andrielly HR Agnellini,** Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padua, 35122 Padova, Italy

**Author contributions:** All authors contributed to this manuscript.

**Supported by** Grant from the Italian Ministry of Health, BANDO GIOVANI RICERCATORI, No. 2009-GR-2009-1558698; Agnellini AHR was granted by Cariparo Fundation Fellowship.

**Conflict-of-interest:** Authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Dott. Barbara Molon,** Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Via Gattamelata, 64, 35128 Padova, Italy. [barbara.molon@unipd.it](mailto:barbara.molon@unipd.it)

**Telephone:** +39-049-7923228

**Fax:** +39-049-7923250

**Received:** October 15, 2014

**Peer-review started:** October 16, 2014

**First decision:** December 17, 2014

**Revised:** January 9, 2015

**Accepted:** February 4, 2015

**Article in press:**

**Published online:**

**Abstract**

Over the last decades, nitric oxide (NO) has been definitively recognised as one of the key players involved in immunity and inflammation. NO generation was originally described in activated macrophages, which still represent the prototype of NO-producing cells. Notwithstanding, additional cell subsets belonging to both innate and adaptive immunity have been documented to sustain NO propagation by means of the enzymatic activity of different nitric oxide synthase isoforms (NOS). Furthermore, due to its chemical characteristics, NO could rapidly react with other free radicalsto generate different reactive nitrogen species (RNS), which have been intriguingly associated with many pathological conditions. Nonetheless, the plethora of NO/RNS-mediated effects still remains extremely puzzling. The aim of this manuscript is to dig into the broad literature on the topic to provide intriguing insights on NO-mediated circuits within immune system. We analysed NO and RNS immunological clues arising from their biochemical properties, immunomodulatory activities and finally dealing with their impact on different pathological scenarios with far prompting intriguing perspectives for their pharmacological targeting.

**Key words:** Nitric oxide; Immune cells; Reactive nitrogen species; Immune diseases; Post-translational modification

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Nitric oxide (NO) is a diffusible molecule, which is responsible for many physiological and pathological conditions. In this work we described some of its chemical characteristics and how it is generated. More, NO could rapidly react with other free radicals to generate different reactive nitrogen species (RNS). Indeed, we addressed the contribution of NO/RNS in different immune cells and how these reactive molecules are pivotal to control cellular responses focusing on inflammatory settings.

Predonzani A, Calì B, Agnellini AHR, Molon B. Spotlights on immunological effects of reactive nitrogen species: When inflammation says NO. *World J Exp Med* 2015; In press

Nitric oxide (NO) is a diffusible molecule, which is involved in many different physiological and pathological conditions. It modulates blood flow[[1](#_ENREF_1),[2](#_ENREF_2)], neural activity[[3](#_ENREF_3)] and immune defence mechanism[[4](#_ENREF_4)].

In biological systems, NO is mainly synthesised enzymatically starting from L-argine according to the following chemical reaction:

NADPH + H+ → NADP+ ½ NADPH + H+ → ½ NADP+

Arginine → N-Hydroxyarginine → Citrulline

O2 → H20 O2 → H20 + NO

This reaction is catalysed by three different enzymes, identified in the ‘90, encoded by different genes with different localization, regulation, catalytic properties and inhibitor sensitivity, called respectively neuronal (nNOS or NOS1), inducible (iNOS or NOS2) and endothelial (eNOS or NOS3) nitric oxide synthase.

Genomic organization is similar among these isoforms suggesting a common ancestral progenitor and is composed by a bidomains structure (an oxigenase domain at N-term and a reductase one at C-term) with a intervening calmodulin (CaM) binding region between the two[[5](#_ENREF_5)]. Calmodulin is necessary for the activity of all these enzymes, even though Ca2+-dependence of NO synthesis distinguishes the NOS isoforms, with nNOS and eNOS having a much higher Ca2+ requirement than iNOS.

nNOS and eNOS are constitutively expressed among several cell types, including the endothelium, platelets, and neurons. Their function is mainly dependent on an intracellular calcium rise, even though other calcium independent mechanisms could impact on it, for example shear stress[[6-10](#_ENREF_6)].

On the other hand iNOS is largerly expressed only after induction by immunologic and inflammatory stimuli and its role in the direct protection against pathogens has been clearly demonstrated. For example, the requirement of iNOS for the eradication of *Mycobacterium tuberculosis* infection has been established[[11](#_ENREF_11)] as well for other Listeria monocytogenes[[12](#_ENREF_12)] and the protozoan parasite Leishmania major[[13](#_ENREF_13),[14](#_ENREF_14)] in ’90. Recent evidence has contributed to clarify mechanisms upon this immune response[[15-17](#_ENREF_15)].

A fourth enzyme has been more recently characterised in rat liver and named mithocontrial NO synthase or mtNOS[[18](#_ENREF_18),[19](#_ENREF_19)]. This latter enzyme has been shown to be constitutively active, calcium dependent and ascribable for mitochondria homeostasis and bioenergetics. Indeed, it has been shown mainly by the group of Ghafourifar that activation of mtNOS upon chemotherapeutic drug administration induces oxidative and nitrative stress, with consequent apoptosis of cells[[20](#_ENREF_20),[21](#_ENREF_21)].

NO is not only the product of NOS enzymes but it is also generated in tissues by either direct disproportionation or reduction of nitrite to NO under the acidic and highly reduced conditions occurring in disease states, such as ischemia[[22-24](#_ENREF_22)]. The biological significance of this alternative source of NO production consists in restoring physiological NO level when enzymatic production is uncoupled or dysregulated, as in atherosclerosis[[25](#_ENREF_25)] or other inflammatory status[[26](#_ENREF_26)].

**NO AND RNS**

Unlike reactive oxygen species (ROS), which are directed into the phagosome, NO is synthesised in the cytoplasm of the cell and diffuse rapidly across cell membrane[[4](#_ENREF_4)]. Due to its chemical characteristics, NO could rapidly react with other free radicals such as O2−• to generate the highly reactive oxidant peroxinitrite (ONOO−) and other reactive nitrogen species (RNS), which have been intriguingly associated with many pathological conditions such as chronic inflammation, atherosclerosis[[27](#_ENREF_27)], diabetes[[28](#_ENREF_28)], inflammatory bowel disease[[29](#_ENREF_29)] and autoimmune diseases[[30](#_ENREF_30)]. Peroxynitrite has multiple cytotoxic effects which are ascribable to aberrant generation of proteins, post-translational modification (PTMs) of the existing ones, DNA damage, activation of poly(ADP-ribose), mitochondrial dysfunction and cell death thus widely affecting transcriptional regulation, gene expression and cell signalling[[31](#_ENREF_31),[32](#_ENREF_32)].

Among the several RNS-induced modifications, the prevalent reaction is the coupling of a NO moiety with sulfhydryl groups on proteins, yielding S-nitrosothiols. The most affected residue is tyrosine. Nowadays, the presence of nitro-tyrosine is commonly accepted as a hallmark of *in situ* inflammation and is associated with many different pathologies, spacing from atherosclerosis, genetic disorders to cancer[[33-36](#_ENREF_33)]. However, NO alone is not capable of nitrating tyrosine thus the accumulation of 3-nitrotyrosine is the reaction product of the other RNS[[37](#_ENREF_37)]. Moreover, under inflammatory conditions, tyrosine nitration may be dependent on the activity of myeloperoxidase, secreted by monocytes and polymorphonuclear neutrophils[[38](#_ENREF_38)].

The biological significance of such modified residues lied in altered protein degradation[[39](#_ENREF_39)], modification in protein properties[[40](#_ENREF_40),[41](#_ENREF_41)], resulting signalling[[42](#_ENREF_42)] and many other phenomena[[43](#_ENREF_43)].

Tyrosine is not the only amino acid that is affected by the presence of RNS. Indeed, most of the amino acids containing aromatic rings could react with RNS and ROS. Among these, modifications of tryptophan were highlighted. Initially, nitration of tryptophan residues in proteins was assessed by means of proteomic assays, such as decreased in tryptophan-associated fluorescence and mass spectrometry, and was associated with decreased functionality of modified proteins[[44](#_ENREF_44)]. However, the majority of the studies so far was unable to detect nitro-tryptophan derivatives *in vivo* due to the lack of good antibodies. This gap was recently filled by Ikeda and collaborators, who developed an antibody specifically reactive with nitrated tryptophan residues[[45](#_ENREF_45)]. This tool boosted the investigation of the presence of such modification in vivo. Ikeda and Yamakura in their studies identified 6-nitrotryptophan residues in extract of PC12 cells, suggesting that NO production drives physiological processes, such as differentiation and morphological changes. These claims were further supported by similar consequences observed upon tyrosine modifications[[46-48](#_ENREF_46)].

**NO, RNS AND INFLAMMATION**

NO has been generally recognised as one of the key players involved in immunity and inflammation. In infectious conditions, NO displays antiviral and antimicrobial activities, both cytotoxic (tissue-damaging) and cytoprotective (tissue-preserving), acting as either an immunostimulatory (proinflammatory) or immunosuppressive (anti-inflammatory) agent. Most of NO-mediated immune effects have been demonstrated to be dependent on the activity of iNOS enzyme which, apart from releasing NO, provokes the depletion of local arginine (together with arginase) in macrophages or other host cells sustaining growth inhibition and death of the parasites[[4](#_ENREF_4)]. Although it has been proposed that efficient pathogen killing require colocalization of iNOS with pathogen-containing compartments[[49](#_ENREF_49),[50](#_ENREF_50)], the fact that NO can diffuse across cell membranes might allow for an antimicrobial activity at distance, even in those cases where NO acts in cells that do not express iNOS[[51](#_ENREF_51)]. However, Olekhnovitch *et al*[[52](#_ENREF_52)] have recently proposed a novel cooperative mechanism of collective NO production to sustain tissue-wide immunity during infections. Indeed authors provide evidence that the diffusion of NO from numerous phagocytes at the site of infection promotes equally effective parasite killing in NO-producing cells and bystander cells[[52](#_ENREF_52)].

Further more, over the last decades, several reports attempted to definitively clarify NO appointment in the immune system[[4](#_ENREF_4)]. Nevertheless, the plethora of heterogeneous NO-mediated responses precludes an univocal definition thus demanding additional investigations. Although NO activity mainly lies on its local spatio-temporal concentration, the phenotype and functional commitment of the immune cells, responsible for its generation, dramatically impact on its own activity. Additionally, given the intrinsic nature of this highly-diffusible uncharged gas, specific immune subsets become selective NO-targets even if not directly involved in its production.

This part of the review aims to provide intriguing spotlights on the role of NO in different immune cell subsets belonging to both innate and adaptive immunity.

Dogmatically, NO is produced by macrophages by means of iNOS activity which is transcriptionally primed by cytokines and microbial stimulation. The sustained generation of NO endows macrophages with cytostatic or cytotoxic activity against pathogens and tumour cells[[53](#_ENREF_53),[54](#_ENREF_54)]. Although the production of NO by human macrophages remains controversial, growing evidence supports this notion providing data for the expression and activity of iNOS and eNOS isoforms in these cells[[55](#_ENREF_55)].

Historically, macrophages were divided into two major categories (M1/M2) depending on their activation status and inflammatory attitude, even though this paradigm has been recently expanded to account for their enormous functional plasticity[[56](#_ENREF_56),[57](#_ENREF_57)].

In 2000, Mills *et al*[[58](#_ENREF_58)] ascertained a relevant metabolic discrepancy between M1/M2 subsets mainly due to a remarkable difference in arginine metabolism[[58](#_ENREF_58)]. Once differentiated, M1 or classically activated macrophages trigger Th1 immune response and secrete high amounts of NO to kill intracellular pathogens and to exert cytotoxicity towards tumour cells[[59](#_ENREF_59)]. On the other side, M2 macrophages express high levels of arginase-I, which competes with iNOS for their common substrate L-arginine, thus preventing NO generation[[60](#_ENREF_60)].

It is thus clear that NO represents a remarkable hallmark of macrophage activation states in pathological settings and that both macrophages and NO fulfil relevant and divergent roles in cancer biology. Mechanistically, it has been proposed that in the early stages of tumour progression, macrophages exploit high concentrations of NO and RNS to kill tumour cell clones. Later on, tumour-reprogramed macrophages produce low levels of NO/RNS, which in turn promote cancer growth and spreading.

Weiss *et al*[[61](#_ENREF_61)] postulated that NO, produced by intratumoural macrophages, represents the crucial determinant for the anti-metastatic potential of IL-2/α-CD40 immunotherapy[[61](#_ENREF_61)]. Conversely, iNOS expression and the coincident NO/RNS generation has been shown to contribute to the immunosuppressive attitude of myeloid-derived suppressor cells (MDSCs), a heterogeneous cell population associated with tumours[[42](#_ENREF_42),[62](#_ENREF_62),[63](#_ENREF_63)].

The *dichotomous* activity of macrophage-derived NO definitely mirrors the aforementioned functional plasticity of these cells in response to environmental cues. The multifaceted role of NO in cancer will be deeply scrutinise in the proper paragraph of this manuscript named “NO, RNS and cancer”.

NO represents a master regulator for the activity of other different immune subsets such as T lymphocytes, dendritic cells (DCs), natural killer cells (NKs) and mast cells. As for macrophages, NO potentially exhibits either positive or negative modulatory properties in all these subsets.

In cancer, it has been postulated that high concentration of NO impairs T cell functions by blocking the signalling cascade downstream of IL-2 binding the IL-2 receptors[[64](#_ENREF_64)]. On the other side, lower concentrations of NO have been shown to promote Th1 differentiation by selectively up-regulating IL-12 receptor beta 2[[65](#_ENREF_65)].

More recently, a cogent paper demonstrated that NO produced by iNOS in activated T cells impairs TH17 cell differentiation trough the nitration of tyrosine residues in RORγt thus regulating IL-17 expression at the transcriptional level[[66](#_ENREF_66)]. An interesting report designated NO as the driving force for the generation of a new subset of regulatory cells (NO-Tregs) via the NO–p53–IL-2–OX40–survivin signalling pathway[[67](#_ENREF_67)]. Nonetheless,by means of syngeneic mouse melanoma model, Jayaraman and colleagues postulated that iNOS, expressed by CD4+ T cells, manifestly inhibits their commitment to Treg by blocking the release of TGF-β1[[68](#_ENREF_68)].

Although compelling studies addressed the role of NO in T cell biology, NO contribution to the regulation of B cell activity remains unclear. Very recently, Giordano and colleagues shed light on the role of NO in regulating humoral immune responses. Indeed, authors suggested that NO generated by both inflammatory Mo-DCs and non-hematopoietic cells potentially regulate T cell-independent (TI)-2 antibody responses by inhibiting BAFF production[[69](#_ENREF_69)].

Dendritic cells (DCs) are the most powerful APCs of the immune system[[70](#_ENREF_70),[71](#_ENREF_71)] representing the bridge between innate and adaptive immunity. In the canonical maturation pathway, microbial products trigger DCs activation, which leads to the production of large amounts of cytokines, especially IL-12 and IFN-α, driving the differentiation of naive T-cells into effector cells[[72](#_ENREF_72),[73](#_ENREF_73)]. Moreover, DCs exposed to inflammatory cytokines rapidly activate other innate protective cells such as natural killer (NK) and NKT cells[[74](#_ENREF_74)]. So far, the role of DCs as potential NO-producing cells has not been fully investigated and data concerning the impact of NO on DC maturation and functions are still debated. During the last years, several reports investigated this issue. Activated murine DCs do essentially express the iNOS isoform in response to cytokines or pathogen stimulation[[75](#_ENREF_75)]. Conversely, the expression of iNOS and the production of NO during the commitment of human DCs are still debated. A recent report claimed that in the human immune system nNOS but not iNOS mediated NO synthesis is pivotal for the maturation and differentiation of these cells[[76](#_ENREF_76)]. Nevertheless, the expression of iNOS as well as NO production clearly participate in the innate defence against intracellular pathogens[[77](#_ENREF_77)].

Additionally, an interesting study by means of real-time metabolic flux analysis pointed out NO as the key metabolic regulator in inflammatory monocyte–derived DCs, expressing iNOS, in response to TLR stimulation[[78](#_ENREF_78)]. In 2003, a groundbreaking publication firstly identified a new TNF/iNOS-producing (Tip)-DC subset in the spleens of Listeria monocytogenes-infected mice[[79](#_ENREF_79)], whose role was recently clarified.Specifically, these cells act as sources of NO in a variety of infections clearly indicating that NO produced by DCs actively participates in both innate and adaptive immunity to pathogens[[80](#_ENREF_80),[81](#_ENREF_81)].

NK cells are effectors of the innate immune system, instrumental for host defence toward infection from bacteria, virus and parasites[[82](#_ENREF_82)]. Moreover, NKs actively participate in tumour surveillance and rejection of transplanted organs[[83](#_ENREF_83)]. Nonetheless, the role of NO in NK cell activation is not completely understood. NOS isoform activity correlates with rodent NK cell-mediated cytotoxicity, as proved by both nitrite accumulation and pharmacological enzymatic interference[[84](#_ENREF_84)]. In humans, the mechanism of NO production in NK cells needs to be clarified. It was proposed that the endogenous NO generation by active eNOS isoform prevents NK cells from activation-induced apoptosis, thereby maintaining cell fitness[[85](#_ENREF_85)].

Mast cells (MCs) are widely distributed throughout the extravascular area in the body where they play versatile roles dealing with innate immunity, IgE-mediated allergy and inflammation. Indeed, they promote neutrophil phagocytosis, lymph node hyperplasia and can directly phagocytise and kill bacteria[[86](#_ENREF_86)].

Data concerning NO/RNS generation by either rodent or human mast cells are still controversial. While investigating this topic in 2004, Swindle and colleagues concluded that activated rodent and human mast cells were unable to generate intracellular NO or to express iNOS[[87](#_ENREF_87)]. According to this study, foregoing reports, indicating a potential NO-like activity in peritoneal mast cells, were misled by the presence of NO-producing macrophage in their cell preparation[[88](#_ENREF_88)].

Conversely, a different group demonstrated the expression of NOS isoforms and production of NO by various MC populations including rat peritoneal MCs, human skin MCs (HSMC) and human mast cell lines (HMC-1 and LAD-2)[[89](#_ENREF_89),[90](#_ENREF_90)].

Nevertheless, as reviewed for other immune subsets, it is well accepted that exogenous NO centrally impacts on mast cell functions. Exploiting a variety of either NO chemical donors or NOS inhbitors on both primary or mast cell lines, introductory reports in the field showed that NO blocks antigen-induced degranulation, mediator production and release[[91](#_ENREF_91)]. Moreover, NO has been shown to promote CD8α up-regulation trough NO-cGMP pathway in rat peritoneal MCs. This remarkable event enlarges CD8 receptor sensitivity to alternative signals and coincidently boosts MC-mediated immune responses[[92](#_ENREF_92)]. It is well known that during activation processes, MCs adhere to the extracellular matrix basically interacting with fibronectin, vitronectin, collagen type I, collagen type IV, and laminin. NO impairs human MC adhesion to the matrix by an alternative mechanism that is mainly indipendent of the direct activation of sGC or RNS generation[[93](#_ENREF_93)] (Table 1 and Figure 1).

**NO, RNS AND AUTOIMMUNE DISEASE**

In addition to promote an effective immune response in the control of infectious diseases, iNOS-mediated NO production may be involved in the dysregulation of immunity, playing a role in chronic inflammatory disorders. Autoimmune diseases could be considered as a chronic inflammatory status where the breakdown of immune tolerance, a complex process involving both genetic and environmental factors, is mainly caused by the post-translational modification of antigens. This occurrence results in the recognition of host proteins as “non-self” and indeed in the initiation of an adaptive immune response. Many inflammatory autoimmune diseases, which are accompanied by oxidative stress, exhibit an excess of reactive chemical species that are able to post-translationally modify proteins, potentially forming neo-epitopes[[30](#_ENREF_30),[96-98](#_ENREF_96)]. These neo-epitopes may directly elicit an adaptive immune response or indirectly sustaining other mechanisms such as the molecular mimicry (a host antigen being “seen” as a “non-self” protein), the exposure of cryptic epitopes (exposure of amino acid sequences after changes in the three-dimensional structure of a protein), the epitope spreading (spreading of antigenicity from a given epitope to other parts of the same protein or other proteins) and the coupling of an autoantigen to an exogenous antigen[[99](#_ENREF_99),[100](#_ENREF_100)]. Increased generation of neo-epitopes/PAMPs/DAMPs may therefore serve as a mechanism for increased uptake and presentation of autoantigens to the immune system, hence for example the accumulation of nitrotyrosine-containing proteins in tissues might induce an autoimmune response and sustain a chronic inflammatory reaction[[96](#_ENREF_96)]. Indeed, murine models of systemic lupus erythematosus (SLE) showed abnormally high levels of RNS compared with normal mice and the systemic blockade of RNS production ameliorates the pathology[[101](#_ENREF_101)]. Further and not surprisingly, elevated levels of anti-nitrotyrosine antibodies have also been measured in the synovial fluid of patients with rheumatoid arthritis and osteoarthritis[[102](#_ENREF_102)] as well as in serum from patients with SLE[[103-105](#_ENREF_103)]. This finding was also verified in patients with active lupus nephritis, who have higher levels of serum nitrotyrosine than those without renal disease, suggesting that overproduction of NO and its derived reactive species may have a pathological role in SLE and lupus nephritis[[106](#_ENREF_106),[107](#_ENREF_107)].

**NO, RNS IN DIABETES**

Diabetes mellitus is a chronic disease characterised by elevated blood sugar levels resulting from either a lack of insulin production or resistance to insulin[[108](#_ENREF_108)]. Hyperglycaemia, glucose autoxidation, accumulation of advanced glycosylation end products (AGEs), enhanced receptor for advanced glycation end product (RAGE) and angiotensin II receptor type 1 (AT1R) signalling as well as elevated levels of free fatty acids and leptin, have been reported to contribute to elevated production of ROS and RNS in diabetic vessels and myocardium[[109](#_ENREF_109),[110](#_ENREF_110)]. Several reports suggest a positive correlation between increased serum and/or vascular 3-nitrotyrosine levels, increased blood pressure and/or endothelial dysfunction in diabetic patients[[111](#_ENREF_111),[112](#_ENREF_112)]. Additionally, high oxidative and nitrative stress in diabetes might induce oxidation and/or nitration of various insulin receptors in peripheral tissues, which may contribute to the development of insulin resistance[[113](#_ENREF_113)]. Moreover, peroxynitrite injury has been implicated in the “metabolic memory” phenomenon, which refers to the therapeutic effects of intensive glycemic control achieved by early intervention in both experimental and clinical studies[[28](#_ENREF_28),[114](#_ENREF_114)]. In diabetic hearts, the persistent myocardial oxidative and nitrative stress might also leads to dysfunction of important antioxidant defense mechanisms, such as the inactivation of superoxide dismutases and catalase and depletion of endogenous antioxidants, as metallothionein and glutathione[[115](#_ENREF_115),[116](#_ENREF_116)] and dysregulation of important redox-dependent transcription factors (*e.g.,* NFE2L2 nuclear factor, erythroid 2-like 2 (Nrf2))[[117](#_ENREF_117),[118](#_ENREF_118)]. However, peroxynitrite-induced protein nitration has been involved in the development of chronic diabetic peripheral neuropathy[[119](#_ENREF_119)] and has been documented in peripheral nerve[[120](#_ENREF_120)], vasa nervorum[[121](#_ENREF_121)], spinal cord and dorsal root ganglion of streptozotocin-diabetic and obese mice[[120](#_ENREF_120),[122](#_ENREF_122)], indicating that diabetes creates not just oxidative, but oxidative-nitrosative stress in the peripheral nervous system.

**NO, RNS AND NEUROINFLAMMATION**

As in other inflammatory disorders, NO plays a dual role in modulating neuroinflammation. On one hand, NO might induce apoptosis of auto-reactive T cells that enter the central nervous system (CNS)[[123](#_ENREF_123)]; on the other hand, NO produced by iNOS within the CNS predominantly contributes to multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) pathogenesis[[124](#_ENREF_124)]. Particularly, NO and peroxynitrite accumulation may affect the components of CNS causing lipid peroxidation and consequent damage of oligodendrocytes[[125](#_ENREF_125)], disruption of blood-brain barrier integrity[[126](#_ENREF_126)], activation of matrix metalloproteinases[[127](#_ENREF_127)], with a block in axonal conduction[[128](#_ENREF_128)] and finally promoting axonal degeneration[[129](#_ENREF_129)]. Interestingly, recent findings on CNS of EAE rats demonstrated that iNOS-derived NO potently inhibits CXCL12 gene expression in a p38-dependent manner *in vitro* and that inhibition *in vivo* of iNOS activity sustains CXCL12 expression and protection of rats from EAE[[130](#_ENREF_130)].

**NO, RNS AND IBD**

Early in the 1990s, various studies based on animal models as well as in humans, indicated that NO may be involved in gastrointestinal inflammation and that it may have a pathogenetic role in inflammatory bowel disease (IBD)[[131](#_ENREF_131)]. Analysis of rectal biopsy specimens from patients with active ulcerative colitis showed higher concentrations of citrulline, the co-product of NO synthase, with respect to those from patients with quiescent disease or a normal histology, indicating that the increased biosynthesis of citrulline might be a consequence of NO synthase activity[[132](#_ENREF_132)]. Additionally, NO produced following the up-regulation of iNOS in colonic epithelial cells has been closely associated with the initiation and maintenance of IBD[[29](#_ENREF_29)]. Notwithstanding, the exact role of NO overproduction in intestinal inflammation remains obscure, since it has been reported that NO production plays a beneficial role in the acute nonspecific colitis settings. On the other hand however, in models of chronic colitis accompanied by a dysregulated immune response, where iNOS is persistently up-regulated, NO displays a detrimental activity on mucosal integrity[[29](#_ENREF_29)]. High levels of NO from iNOS may infact exacerbate the clinicopathological features of colitis by direct cytotoxicity, activation of neutrophils[[133](#_ENREF_133)], vasodilatation and reduced smooth muscle tone[[134](#_ENREF_134)].

**NO, RNS AND CANCER**

As already mentioned, NO and its derivative have been extensively associated with many different pathologies. The connection between cancer and inflammation dates back to 1863, when Rudolf Virchow noted leucocytes in neoplastic tissues, suggesting that the “lymphoreticular infiltrate” reflected the origin of cancer at sites of chronic inflammation[[135](#_ENREF_135)]. Moreover, smouldering inflammation increases the risk of developing many types of cancer, including bladder, cervical, gastric, intestinal, oesophageal, ovarian, prostate and thyroid cancer[[136](#_ENREF_136),[137](#_ENREF_137)], thus representing one of the novel additional hallmarks of cancers[[138](#_ENREF_138)]. As a result of chronic inflammation, tumour microenvironment harbours different corrupted resident or purposely recruited cells which exert conflicting functions establishing a peculiar cytokine milieu[[139](#_ENREF_139)]. Among these, tumour-associated macrophage (TAM) and myeloid-derived suppressor cells (MDSCs) present in tumour overexpress iNOS and release oxidizing molecules, such as hydrogen peroxide (H2O2) and peroxynitrite (ONOO–) which cause nitration and nitrosylation of components of the T cell receptor (TCR) signalling complex, and the loss of the TCR δ-chain, thereby inhibiting T cell activation through the TCR and contributing to tumour progression[[95](#_ENREF_95),[140](#_ENREF_140),[141](#_ENREF_141)]. More recently, Molon *et al*[[142](#_ENREF_142)], in 2011, have demonstrated that chemokine nitration prevents intratumoural infiltration of antigen-specific T cells, which remained confined at the edge of tumours being unable to reach the central core due to the nitration of CCL2, a master chemokine[[142](#_ENREF_142)]. Moreover, several investigators have reported the expression of iNOS by malignant cells or within the tumour microenvironment, both at mRNA and protein level. In breast carcinoma, an initial study suggested that iNOS activity was higher in less differentiated tumours and detected predominantly in TAMs[[143](#_ENREF_143)]. Subsequently, other reports demonstrated that iNOS was also expressed by breast carcinoma cells and positively correlated with tumour stage[[144](#_ENREF_144)] and microvessel density[[145](#_ENREF_145)]. In addition to breast cancer, iNOS is markedly expressed in approximately 60% of human colon adenomas and in 20%-25% of colon carcinomas, while the expression is either low or absent in the surrounding normal tissues. Similar results were obtained for human ovarian cancer and melanoma. Other cancers that express iNOS are head and neck, oesophagus, lung, prostate, bladder and pancreatic carcinomas, brain tumours, Kaposi’ s sarcoma, mesothelioma, and haematological malignancies[[63](#_ENREF_63)]. Moreover, the eNOS has been found in both endothelial and tumour cells of breast carcinomas, and the nNOS has been detected in some oligodendroglioma and neuroblastoma cell lines. However, the role of NO in cancer biology has not been clearly elucidated yet, since various studies have shown that NO may either promote or inhibit tumour progression and metastasis. The net effect of NO in tumours seems to depend on the activity and localization of NOS isoforms, concentration and duration of NO exposure, cellular sensitivity and hypoxia/re-oxygenation process within tumour microenvironment[[146](#_ENREF_146)]. In general, high concentrations of NO and RNS can arrest cell cycle (cytostatic effect) or induce cell death, whereas low concentrations may protect cells from apoptosis. In fact, generation of high levels of NO/RNS is a very effective tool to induce cell death, and macrophages use it as a major weapon in their arsenal against invading pathogens and tumour cells[[147](#_ENREF_147)]. High levels of NO/RNS post-translationally modify death-related target proteins, as the death receptors of the TNF-α superfamily, and block respiration in target cells by affecting the mitochondrial respiratory chain and its outer membrane permeability and thus leading to the release of cytochrome c and apoptosis initiation[[148](#_ENREF_148),[149](#_ENREF_149)]. Moreover, high NO concentrations, oxidizing and/or deaminating the DNA bases, result in DNA breaks, DNA base modifications or DNA cross-links, which cause mutations that may either activate oncogenes or deactivate tumour suppressor genes. In addition, NO/RNS-driven protein modifications such as S-nitrosylation or nitration may inhibit proteins belonging to the DNA repair systems, driving to genomic instability[[150](#_ENREF_150),[151](#_ENREF_151)]. Importantly, DNA damages that cannot be repaired cause apoptosis induction, by the activation of DNA-damage-sensing proteins (*e.g.*, p53, PARP, DNA-PK, BRCA1, ATM)[[152](#_ENREF_152)]. However, NO has been demonstrated to inhibit programmed cell death in endothelial cells and some liver cancer cell lines, mainly through S-nitrosylation of the active-site cysteine of caspases[[153](#_ENREF_153)], thus perpetuating mutations and consequently sustaining transformation[[154](#_ENREF_154),[155](#_ENREF_155)]. On the other hand, NO may induce apoptosis either via down-regulation of the anti apoptotic protein survivin, as observed in human lung carcinoma cells[[156](#_ENREF_156)], or up-regulation of Fas expression, as shown in ovarian carcinoma cell lines, through the specific inactivation of the transcription repressor yin-yang-1, which binds to the silencer region of the Fas promoter[[157](#_ENREF_157)]. Besides enhancing cytotoxicity, NO plays a role in angiogenesis and metastasis since several reports showed a positive correlation between NOS expression/activity in tumour tissues and lymphatic metastasis in head and neck, thyroid, breast, stomach, gallbladder cancers[[146](#_ENREF_146),[158](#_ENREF_158)] and melanoma[[159](#_ENREF_159)]. As under physiologic conditions, NO maintains blood flow by dilatation of arterial vessels, promotes perivascular cell recruitment and vessel remodelling and maturation within tumours[[146](#_ENREF_146)]. NO exposure of A-431 squamous carcinoma cells and MDA-MB-231 breast cancer cells was, in fact, able to induce VEGF-C expression, which mediates lymphangiogenesis and metastasis[[160](#_ENREF_160)]. However, NO may also inhibit the aggregation of platelets through a cGMP-dependent mechanism, preventing aggregates formation with tumour cells, which may facilitate their adhesion to vascular endothelial cells and haematogeneous dissemination[[161](#_ENREF_161)]. Finally, as previously mentioned, NO/RNS can suppress tumour-specific adaptive immunity through several mechanisms. One mechanism involves the inhibition of phosphorylation, and thereby the activation of important signalling proteins in the IL-2-receptor pathway (including Janus activated kinase 1 (JAK1), JAK3, STAT5, extracellular-signal-regulated kinase (ERK) and AKT) in T cells[[162](#_ENREF_162)]. Additionally, NO promotes tumour immunosuppression, by affecting the stability of IL-2 encoding mRNA and the release of IL-2 by activated human T cells[[163](#_ENREF_163)]. Finally, NO/RNS may dampen anti-tumour immunity through post-translational modifications of key proteins for T cell activation, such as CD8 and TCR complex α/β chains molecules[[42](#_ENREF_42)] and T lymphocyte recruitment to the tumour site, such as the chemokine CCL2[[142](#_ENREF_142)]. Thus, interfering with NO/RNS production within tumour microenvironment may represent a promising successful strategy to implement the efficacy of anti-tumour therapy alone or, even better, in combination with conventional chemotherapy, radiotherapy, photodynamic therapy and immunotherapy approaches[[164-166](#_ENREF_164)] (Table 2).

**CONCLUDING REMARKS**

Over the last decades, the role of NO in the immune system has been extensively reviewed. While investigating NO-mediated responses, a number of reports argued for either a NO-stimulatory or -inhibitory activity in distinctive immune events. Nonetheless, the generation of NO in several immune cell subsets remains still controversial thus demanding additional studies.

So far, a general consensus in the field has been achieved highlighting the indisputably role of this diffusible mediator in shaping immune activities.

This manuscript aims to provide spotlights on NO-moulded biology specifically focussing on its pivotal participation in distinctive inflammatory programs. Indeed throughout this review, we scrutinised the role of NO in selective scenarios starting with the description of its biochemical properties, immunomodulatory activities and finally dealing with its remarkable impact on different pathological settings. Collectively all the aforementioned investigations pointed out the relevance of NO-mediated effects in the regulation of either innate or adaptive immunity.

Additionally, the combination of NO with other reactive species originates RNS, which are actively involved in several pathological conditions such as chronic inflammation, autoimmune diseases and cancer. Basically, RNS generate and amplify distinctive inflammatory circuits by affecting protein structure and functions, gene expression, cell signalling and cell death.

Hence, this manuscript also emphasises the duplicity of NO-mediated responses in distinctive immune cell subsets. This dichotomous attitude apparently hinders the identification of NO as a foolproof target thus preventing the identification of feasible therapeutic strategies that could be rapidly delivered to the clinic. Nonetheless, we believe that the plasticity of NO signals could be potentially exploited for the development of new focussed pharmacological approaches.

Of note, RNS-mediated PTMs potentially represent a novel marker for monitoring the efficacy of therapy during disease treatment or in the follow-up care.

This pursuit requires a thorough understanding of NO/RNS biology in the context of the immune system thus opening the way for intriguing investigations.

**REFERENCES**

1 **Wolin MS**. Reactive oxygen species and the control of vascular function. *Am J Physiol Heart Circ Physiol* 2009; **296**: H539-H549 [PMID: 19151250 DOI: 10.1152/ajpheart.01167.2008]

2 **Wolin MS.** Reactive Oxygen Species and Nitric Oxide in Vascular Function, in Studies on Pediatric Disorders. Tsukahara H and Kaneko K Editors. Springer New York, 2014: 15-33

3 **Steinert JR**, Robinson SW, Tong H, Haustein MD, Kopp-Scheinpflug C, Forsythe ID. Nitric oxide is an activity-dependent regulator of target neuron intrinsic excitability. *Neuron* 2011; **71**: 291-305 [PMID: 21791288 DOI: 10.1016/j.neuron.2011.05.037]

4 **Bogdan C**. Nitric oxide and the immune response. *Nat Immunol* 2001; **2**: 907-916 [PMID: 11577346 DOI: 10.1038/ni1001-907]

5 **Smith BC**, Underbakke ES, Kulp DW, Schief WR, Marletta MA. Nitric oxide synthase domain interfaces regulate electron transfer and calmodulin activation. *Proc Natl Acad Sci USA* 2013; **110**: E3577-E3586 [PMID: 24003111 DOI: 10.1073/pnas.1313331110]

6 **Wang W**, Ha CH, Jhun BS, Wong C, Jain MK, Jin ZG. Fluid shear stress stimulates phosphorylation-dependent nuclear export of HDAC5 and mediates expression of KLF2 and eNOS. *Blood* 2010; **115**: 2971-2979 [PMID: 20042720 DOI: 10.1182/blood-2009-05-224824]

7 **Suhr F**, Brenig J, Müller R, Behrens H, Bloch W, Grau M. Moderate exercise promotes human RBC-NOS activity, NO production and deformability through Akt kinase pathway. *PLoS One* 2012; **7**: e45982 [PMID: 23049912 DOI: 10.1371/journal.pone.0045982]

8 **Ramírez-Vélez R**, Bustamante J, Czerniczyniec A, Aguilar de Plata AC, Lores-Arnaiz S. Effect of exercise training on eNOS expression, NO production and oxygen metabolism in human placenta. *PLoS One* 2013; **8**: e80225 [PMID: 24244656 DOI: 10.1371/journal.pone.0080225]

9 **Kasamatsu S**, Watanabe Y, Sawa T, Akaike T, Ihara H. Redox signal regulation via nNOS phosphorylation at Ser847 in PC12 cells and rat cerebellar granule neurons. *Biochem J* 2014; **459**: 251-263 [PMID: 24499461 DOI: 10.1042/BJ20131262]

10 **Song T**, Hatano N, Sugimoto K, Horii M, Yamaguchi F, Tokuda M, Miyamoto Y, Kambe T, Watanabe Y. Nitric oxide prevents phosphorylation of neuronal nitric oxide synthase at serine1412 by inhibiting the Akt/PKB and CaM-K II signaling pathways. *Int J Mol Med* 2012; **30**: 15-20 [PMID: 22576624]

11 **MacMicking JD**, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. *Proc Natl Acad Sci USA* 1997; **94**: 5243-5248 [PMID: 9144222 DOI: 10.1073/pnas.94.10.5243]

12 **MacMicking JD**, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. *Cell* 1995; **81**: 641-650 [PMID: 7538909 DOI: 10.1016/0092-8674(95)90085-3]

13 **Wei XQ**, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, Liew FY. Altered immune responses in mice lacking inducible nitric oxide synthase. *Nature* 1995; **375**: 408-411 [PMID: 7539113 DOI: 10.1038/375408a0]

14 **Diefenbach A**, Schindler H, Donhauser N, Lorenz E, Laskay T, MacMicking J, Röllinghoff M, Gresser I, Bogdan C. Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. *Immunity* 1998; **8**: 77-87 [PMID: 9462513 DOI: 10.1016/S1074-7613(00)80460-4]

15 **Elks PM**, Brizee S, van der Vaart M, Walmsley SR, van Eeden FJ, Renshaw SA, Meijer AH. Hypoxia inducible factor signaling modulates susceptibility to mycobacterial infection via a nitric oxide dependent mechanism. *PLoS Pathog* 2013; **9**: e1003789 [PMID: 24367256 DOI: 10.1371/journal.ppat.1003789]

16 **Thi EP**, Hong CJ, Sanghera G, Reiner NE. Identification of the Mycobacterium tuberculosis protein PE-PGRS62 as a novel effector that functions to block phagosome maturation and inhibit iNOS expression. *Cell Microbiol* 2013; **15**: 795-808 [PMID: 23167250 DOI: 10.1111/cmi.12073]

17 **Kuang Z**, Lewis RS, Curtis JM, Zhan Y, Saunders BM, Babon JJ, Kolesnik TB, Low A, Masters SL, Willson TA, Kedzierski L, Yao S, Handman E, Norton RS, Nicholson SE. The SPRY domain-containing SOCS box protein SPSB2 targets iNOS for proteasomal degradation. *J Cell Biol* 2010; **190**: 129-141 [PMID: 20603330 DOI: 10.1083/jcb.200912087]

18 **Ghafourifar P**, Richter C. Nitric oxide synthase activity in mitochondria. *FEBS Lett* 1997; **418**: 291-296 [PMID: 9428730 DOI: 10.1016/S0014-5793(97)01397-5]

19 **Tatoyan A**, Giulivi C. Purification and characterization of a nitric-oxide synthase from rat liver mitochondria. *J Biol Chem* 1998; **273**: 11044-11048 [PMID: 9556587 DOI: 10.1074/jbc.273.18.11044]

20 **Parihar A**, Parihar MS, Ghafourifar P. Significance of mitochondrial calcium and nitric oxide for apoptosis of human breast cancer cells induced by tamoxifen and etoposide. *Int J Mol Med* 2008; **21**: 317-324 [PMID: 18288379]

21 **Nazarewicz RR**, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, Ghafourifar P. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. *Cancer Res* 2007; **67**: 1282-1290 [PMID: 17283165 DOI: 10.1158/0008-5472.CAN-06-3099]

22 **Zweier JL**, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. *Nat Med* 1995; **1**: 804-809 [PMID: 7585184 DOI: 10.1038/nm0895-804]

23 **Feelisch M**, Fernandez BO, Bryan NS, Garcia-Saura MF, Bauer S, Whitlock DR, Ford PC, Janero DR, Rodriguez J, Ashrafian H. Tissue processing of nitrite in hypoxia: an intricate interplay of nitric oxide-generating and -scavenging systems. *J Biol Chem* 2008; **283**: 33927-33934 [PMID: 18835812 DOI: 10.1074/jbc.M806654200]

24 **Madigan M**, Zuckerbraun B. Therapeutic Potential of the Nitrite-Generated NO Pathway in Vascular Dysfunction. *Front Immunol* 2013; **4**: 174 [PMID: 23847616 DOI: 10.3389/fimmu.2013.00174]

25 **Swirski FK**, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. *J Clin Invest* 2007; **117**: 195-205 [PMID: 17200719 DOI: 10.1172/JCI29950]

26 **Kossmann S**, Hu H, Steven S, Schönfelder T, Fraccarollo D, Mikhed Y, Brähler M, Knorr M, Brandt M, Karbach SH, Becker C, Oelze M, Bauersachs J, Widder J, Münzel T, Daiber A, Wenzel P. Inflammatory monocytes determine endothelial nitric-oxide synthase uncoupling and nitro-oxidative stress induced by angiotensin II. *J Biol Chem* 2014; **289**: 27540-27550 [PMID: 25143378 DOI: 10.1074/jbc.M114.604231]

27 **Li H**, Horke S, Förstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. *Atherosclerosis* 2014; **237**: 208-219 [PMID: 25244505 DOI: 10.1016/j.atherosclerosis.2014.09.001]

28 **Kowluru RA**, Kanwar M, Kennedy A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. *Exp Diabetes Res* 2007; **2007**: 21976 [PMID: 17641740]

29 **Kolios G**, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. *Immunology* 2004; **113**: 427-437 [PMID: 15554920 DOI: 10.1111/j.1365-2567.2004.01984.x]

30 **Ryan BJ**, Nissim A, Winyard PG. Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. *Redox Biol* 2014; **2**: 715-724 [PMID: 24955328 DOI: 10.1016/j.redox.2014.05.004]

31 **Pacher P**, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 2007; **87**: 315-424 [PMID: 17237348 DOI: 10.1152/physrev.00029.2006]

32 **Szabó C**, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. *Nat Rev Drug Discov* 2007; **6**: 662-680 [PMID: 17667957 DOI: 10.1038/nrd2222]

33 **Vitner EB**, Farfel-Becker T, Eilam R, Biton I, Futerman AH. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. *Brain* 2012; **135**: 1724-1735 [PMID: 22566609 DOI: 10.1093/brain/aws095]

34 **Shu L**, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JM, Hollak CE, Shayman JA. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. *Kidney Int* 2014; **86**: 58-66 [PMID: 24402087 DOI: 10.1038/ki.2013.520]

35 **Maturu P**, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. *Transl Oncol* 2014; **7**: 484-492 [PMID: 24969538 DOI: 10.1016/j.tranon.2014.05.008]

36 **Aulak KS**, Miyagi M, Yan L, West KA, Massillon D, Crabb JW, Stuehr DJ. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. *Proc Natl Acad Sci U S A* 2001; **98**: 12056-12061 [PMID: 11593016 DOI: 10.1073/pnas.221269198]

37 **Beckman JS**. Oxidative damage and tyrosine nitration from peroxynitrite. *Chem Res Toxicol* 1996; **9**: 836-844 [PMID: 8828918 DOI: 10.1021/tx9501445]

38 **Eiserich JP**, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. *Nature* 1998; **391**: 393-397 [PMID: 9450756 DOI: 10.1038/34923]

39 **Wagner AH**, Hildebrandt A, Baumgarten S, Jungmann A, Müller OJ, Sharov VS, Schöneich C, Hecker M. Tyrosine nitration limits stretch-induced CD40 expression and disconnects CD40 signaling in human endothelial cells. *Blood* 2011; **118**: 3734-3742 [PMID: 21832282 DOI: 10.1182/blood-2010-11-320259]

40 **Danielson SR**, Held JM, Schilling B, Oo M, Gibson BW, Andersen JK. Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. *Anal Chem* 2009; **81**: 7823-7828 [PMID: 19697948 DOI: 10.1021/ac901176t]

41 **Osoata GO**, Yamamura S, Ito M, Vuppusetty C, Adcock IM, Barnes PJ, Ito K. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. *Biochem Biophys Res Commun* 2009; **384**: 366-371 [PMID: 19410558 DOI: 10.1016/j.bbrc.2009.04.128]

42 **Nagaraj S**, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. *Nat Med* 2007; **13**: 828-835 [PMID: 17603493 DOI: 10.1038/nm1609]

43 **Abello N**, Kerstjens HA, Postma DS, Bischoff R. Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins. *J Proteome Res* 2009; **8**: 3222-3238 [PMID: 19415921 DOI: 10.1021/pr900039c]

44 **Yamakura F**, Matsumoto T, Fujimura T, Taka H, Murayama K, Imai T, Uchida K. Modification of a single tryptophan residue in human Cu,Zn-superoxide dismutase by peroxynitrite in the presence of bicarbonate. *Biochim Biophys Acta* 2001; **1548**: 38-46 [PMID: 11451436 DOI: 10.1016/S0167-4838(01)00212-6]

45 **Ikeda K**, Yukihiro Hiraoka B, Iwai H, Matsumoto T, Mineki R, Taka H, Takamori K, Ogawa H, Yamakura F. Detection of 6-nitrotryptophan in proteins by Western blot analysis and its application for peroxynitrite-treated PC12 cells. *Nitric Oxide* 2007; **16**: 18-28 [PMID: 16765071 DOI: 10.1016/j.niox.2006.04.263]

46 **Redondo-Horcajo M**, Romero N, Martínez-Acedo P, Martínez-Ruiz A, Quijano C, Lourenço CF, Movilla N, Enríquez JA, Rodríguez-Pascual F, Rial E, Radi R, Vázquez J, Lamas S. Cyclosporine A-induced nitration of tyrosine 34 MnSOD in endothelial cells: role of mitochondrial superoxide. *Cardiovasc Res* 2010; **87**: 356-365 [PMID: 20106845 DOI: 10.1093/cvr/cvq028]

47 **Tedeschi G**, Cappelletti G, Nonnis S, Taverna F, Negri A, Ronchi C, Ronchi S. Tyrosine nitration is a novel post-translational modification occurring on the neural intermediate filament protein peripherin. *Neurochem Res* 2007; **32**: 433-441 [PMID: 17268851 DOI: 10.1007/s11064-006-9244-2]

48 **Llovera M**, Pearson JD, Moreno C, Riveros-Moreno V. Impaired response to interferon-gamma in activated macrophages due to tyrosine nitration of STAT1 by endogenous nitric oxide. *Br J Pharmacol* 2001; **132**: 419-426 [PMID: 11159690 DOI: 10.1038/sj.bjp.0703838]

49 **Chakravortty D**, Hansen-Wester I, Hensel M. Salmonella pathogenicity island 2 mediates protection of intracellular Salmonella from reactive nitrogen intermediates. *J Exp Med* 2002; **195**: 1155-1166 [PMID: 11994420 DOI: 10.1084/jem.20011547]

50 **Davis AS**, Vergne I, Master SS, Kyei GB, Chua J, Deretic V. Mechanism of inducible nitric oxide synthase exclusion from mycobacterial phagosomes. *PLoS Pathog* 2007; **3**: e186 [PMID: 18069890 DOI: 10.1371/journal.ppat.0030186]

51 **Bogdan C**, Donhauser N, Döring R, Röllinghoff M, Diefenbach A, Rittig MG. Fibroblasts as host cells in latent leishmaniosis. *J Exp Med* 2000; **191**: 2121-2130 [PMID: 10859337 DOI: 10.1084/jem.191.12.2121]

52 **Olekhnovitch R**, Ryffel B, Müller AJ, Bousso P. Collective nitric oxide production provides tissue-wide immunity during Leishmania infection. *J Clin Invest* 2014; **124**: 1711-1722 [PMID: 24614106 DOI: 10.1172/JCI72058]

53 **MacMicking J**, Xie QW, Nathan C. Nitric oxide and macrophage function. *Annu Rev Immunol* 1997; **15**: 323-350 [PMID: 9143691 DOI: 10.1146/annurev.immunol.15.1.323]

54 **Farias-Eisner R**, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. *Proc Natl Acad Sci USA* 1994; **91**: 9407-9411 [PMID: 7937779 DOI: 10.1073/pnas.91.20.9407]

55 **Nicholson S**, Bonecini-Almeida Mda G, Lapa e Silva JR, Nathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. *J Exp Med* 1996; **183**: 2293-2302 [PMID: 8642338 DOI: 10.1084/jem.183.5.2293]

56 **Biswas SK**, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nat Immunol* 2010; **11**: 889-896 [PMID: 20856220 DOI: 10.1038/ni.1937]

57 **Murray PJ**, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 2014; **41**: 14-20 [PMID: 25035950 DOI: 10.1016/j.immuni.2014.06.008]

58 **Mills CD**, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. *J Immunol* 2000; **164**: 6166-6173 [PMID: 10843666 DOI: 10.4049/jimmunol.164.12.6166]

59 **Sica A**, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *J Clin Invest* 2012; **122**: 787-795 [PMID: 22378047 DOI: 10.1172/JCI59643]

60 **Gordon S**, Martinez FO. Alternative activation of macrophages: mechanism and functions. *Immunity* 2010; **32**: 593-604 [PMID: 20510870 DOI: 10.1016/j.immuni.2010.05.007]

61 **Weiss JM**, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK, Murphy WJ, Harris CC, Wink DA, Wiltrout RH. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. *J Exp Med* 2010; **207**: 2455-2467 [PMID: 20921282 DOI: 10.1084/jem.20100670]

62 **Serafini P**, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. *Semin Cancer Biol* 2006; **16**: 53-65 [PMID: 16168663 DOI: 10.1016/j.semcancer.2005.07.005]

63 **Rahat MA**, Hemmerlein B. Macrophage-tumor cell interactions regulate the function of nitric oxide. *Front Physiol* 2013; **4**: 144 [PMID: 23785333 DOI: 10.3389/fphys.2013.00144]

64 **Bronte V**, Zanovello P. Regulation of immune responses by L-arginine metabolism. *Nat Rev Immunol* 2005; **5**: 641-654 [PMID: 16056256 DOI: 10.1038/nri1668]

65 **Niedbala W**, Wei XQ, Campbell C, Thomson D, Komai-Koma M, Liew FY. Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP. *Proc Natl Acad Sci USA* 2002; **99**: 16186-16191 [PMID: 12451176 DOI: 10.1073/pnas.252464599]

66 **Jianjun Yang R**, Lu G, Shen Y, Peng L, Zhu C, Cui M, Wang W, Arnaboldi P, Tang M, Gupta M, Qi CF, Jayaraman P, Zhu H, Jiang B, Chen SH, He JC, Ting AT, Zhou MM, Kuchroo VK, Morse HC, Ozato K, Sikora AG, Xiong H. T cell–derived inducible nitric oxide synthase switches off Th17 cell differentiation. *J Exp Med* 2013; **210**: 1447-1462 [PMID: 23797094 DOI: 10.1084/jem.20122494]

67 **Niedbala W**, Cai B, Liu H, Pitman N, Chang L, Liew FY. Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40. *Proc Natl Acad Sci U S A* 2007; **104**: 15478-15483 [PMID: 17875988 DOI: 10.1073/pnas.0703725104]

68 **Jayaraman P**, Alfarano MG, Svider PF, Parikh F, Lu G, Kidwai S, Xiong H, Sikora AG. iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity. *Clin Cancer Res* 2014; **20**: 6439-6451 [PMID: 25278453 DOI: 10.1158/1078-0432.CCR-13-3409]

69 **Giordano D**, Draves KE, Li C, Hohl TM, Clark EA. Nitric oxide regulates BAFF expression and T cell-independent antibody responses. *J Immunol* 2014; **193**: 1110-1120 [PMID: 24951820 DOI: 10.4049/jimmunol.1303158]

70 **Banchereau J**, Steinman RM. Dendritic cells and the control of immunity. *Nature* 1998; **392**: 245-252 [PMID: 9521319 DOI: 10.1038/32588]

71 **Villadangos JA**, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. *Nat Rev Immunol* 2007; **7**: 543-555 [PMID: 17589544 DOI: 10.1038/nri2103]

72 **Smith-Garvin JE**, Koretzky GA, Jordan MS. T cell activation. *Annu Rev Immunol* 2009; **27**: 591-619 [PMID: 19132916 DOI: 10.1146/annurev.immunol.021908.132706]

73 **Haring JS**, Badovinac VP, Harty JT. Inflaming the CD8+ T cell response. *Immunity* 2006; **25**: 19-29 [PMID: 16860754 DOI: 10.1016/j.immuni.2006.07.001]

74 **Fernandez NC**, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. *Nat Med* 1999; **5**: 405-411 [PMID: 10202929 DOI: 10.1038/7403]

75 **Lu L**, Bonham CA, Chambers FG, Watkins SC, Hoffman RA, Simmons RL, Thomson AW. Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. *J Immunol* 1996; **157**: 3577-3586 [PMID: 8871658]

76 **Adler HS**, Simon A, Graulich E, Habermeier A, Bacher N, Friebe A, Closs EI, Steinbrink K. Neuronal nitric oxide synthase modulates maturation of human dendritic cells. *J Immunol* 2010; **184**: 6025-6034 [PMID: 20421643 DOI: 10.4049/jimmunol.0901327]

77 **Eriksson S**, Chambers BJ, Rhen M. Nitric oxide produced by murine dendritic cells is cytotoxic for intracellular Salmonella enterica sv. Typhimurium. *Scand J Immunol* 2003; **58**: 493-502 [PMID: 14629621 DOI: 10.1046/j.1365-3083.2003.01330.x]

78 **Everts B**, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE, Pearce EL, Pearce EJ. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. *Blood* 2012; **120**: 1422-1431 [PMID: 22786879 DOI: 10.1182/blood-2012-03-419747]

79 **Serbina NV**, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. *Immunity* 2003; **19**: 59-70 [PMID: 12871639 DOI: 10.1016/S1074-7613(03)00171-7]

80 **De Trez C**, Magez S, Akira S, Ryffel B, Carlier Y, Muraille E. iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. *PLoS Pathog* 2009; **5**: e1000494 [PMID: 19557162 DOI: 10.1371/journal.ppat.1000494]

81 **Aldridge JR**, Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, Franks J, Brown SA, Doherty PC, Webster RG, Thomas PG. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. *Proc Natl Acad Sci U S A* 2009; **106**: 5306-5311 [PMID: 19279209 DOI: 10.1073/pnas.0900655106]

82 **Trinchieri G**. Biology of natural killer cells. *Adv Immunol* 1989; **47**: 187-376 [PMID: 2683611 DOI: 10.1016/S0065-2776(08)60664-1]

83 **Vivier E**, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. *Nat Immunol* 2008; **9**: 503-510 [PMID: 18425107 DOI: 10.1038/ni1582]

84 **Cifone MG**, Ulisse S, Santoni A. Natural killer cells and nitric oxide. *Int Immunopharmacol* 2001; **1**: 1513-1524 [PMID: 11515816 DOI: 10.1016/S1567-5769(01)00095-9]

85 **Furuke K**, Burd PR, Horvath-Arcidiacono JA, Hori K, Mostowski H, Bloom ET. Human NK cells express endothelial nitric oxide synthase, and nitric oxide protects them from activation-induced cell death by regulating expression of TNF-alpha. *J Immunol* 1999; **163**: 1473-1480 [PMID: 10415049]

86 **da Silva EZ**, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. *J Histochem Cytochem* 2014; **62**: 698-738 [PMID: 25062998 DOI: 10.1369/0022155414545334]

87 **Swindle EJ**, Metcalfe DD, Coleman JW. Rodent and human mast cells produce functionally significant intracellular reactive oxygen species but not nitric oxide. *J Biol Chem* 2004; **279**: 48751-48759 [PMID: 15361524 DOI: 10.1074/jbc.M409738200]

88 **Salvemini D**, Masini E, Anggard E, Mannaioni PF, Vane J. Synthesis of a nitric oxide-like factor from L-arginine by rat serosal mast cells: stimulation of guanylate cyclase and inhibition of platelet aggregation. *Biochem Biophys Res Commun* 1990; **169**: 596-601 [PMID: 1972620 DOI: 10.1016/0006-291X(90)90372-T]

89 **Gilchrist M**, McCauley SD, Befus AD. Expression, localization, and regulation of NOS in human mast cell lines: effects on leukotriene production. *Blood* 2004; **104**: 462-469 [PMID: 15044250 DOI: 10.1182/blood-2003-08-2990]

90 **Gilchrist M**, Savoie M, Nohara O, Wills FL, Wallace JL, Befus AD. Nitric oxide synthase and nitric oxide production in in vivo-derived mast cells. *J Leukoc Biol* 2002; **71**: 618-624 [PMID: 11927648]

91 **Salvemini D.** Nitric Oxide: A Regulatory Mediator of Mast Cell Reactivity. *J Cardiovas Pharma* 1991; **17:** S264 Available from: URL: http://journals.lww.com/cardiovascularpharm/Abstract/1991/17003/Nitric\_Oxide\_\_A\_Regulatory\_Mediator\_of\_Mast\_Cell.47.aspx

92 **Nohara O**, Kulka M, Déry RE, Wills FL, Hirji NS, Gilchrist M, Befus AD. Regulation of CD8 expression in mast cells by exogenous or endogenous nitric oxide. *J Immunol* 2001; **167**: 5935-5939 [PMID: 11698471 DOI: 10.4049/jimmunol.167.10.5935]

93 **Forsythe P**, Befus AD. Inhibition of calpain is a component of nitric oxide-induced down-regulation of human mast cell adhesion. *J Immunol* 2003; **170**: 287-293 [PMID: 12496411 DOI: 10.4049/jimmunol.170.1.287]

94 **Hammami I**, Chen J, Bronte V, DeCrescenzo G, Jolicoeur M. L-glutamine is a key parameter in the immunosuppression phenomenon. *Biochem Biophys Res Commun* 2012; **425**: 724-729 [PMID: 22885179 DOI: 10.1016/j.bbrc.2012.07.139]

95 **Gabrilovich DI**, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol* 2012; **12**: 253-268 [PMID: 22437938 DOI: 10.1038/nri3175]

96 **Birnboim HC**, Lemay AM, Lam DK, Goldstein R, Webb JR. Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. *J Immunol* 2003; **171**: 528-532 [PMID: 12847213 DOI: 10.4049/jimmunol.171.2.528]

97 **Ohmori H**, Oka M, Nishikawa Y, Shigemitsu H, Takeuchi M, Magari M, Kanayama N. Immunogenicity of autologous IgG bearing the inflammation-associated marker 3-nitrotyrosine. *Immunol Lett* 2005; **96**: 47-54 [PMID: 15585307 DOI: 10.1016/j.imlet.2004.07.004]

98 **Hardy LL**, Wick DA, Webb JR. Conversion of tyrosine to the inflammation-associated analog 3'-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells. *J Immunol* 2008; **180**: 5956-5962 [PMID: 18424715 DOI: 10.4049/jimmunol.180.9.5956]

99 **Kalluri R**, Cantley LG, Kerjaschki D, Neilson EG. Reactive oxygen species expose cryptic epitopes associated with autoimmune goodpasture syndrome. *J Biol Chem* 2000; **275**: 20027-20032 [PMID: 10748075 DOI: 10.1074/jbc.M904549199]

100 **Binder CJ**, Hörkkö S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. *Nat Med* 2003; **9**: 736-743 [PMID: 12740573 DOI: 10.1038/nm876]

101 **Habib S**, Moinuddin R. Peroxynitrite-modified DNA: a better antigen for systemic lupus erythematosus anti-DNA autoantibodies. *Biotechnol Appl Biochem* 2006; **43**: 65-70 [PMID: 16232128]

102 **Khan F**, Siddiqui AA. Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus. *Clin Chim Acta* 2006; **370**: 100-107 [PMID: 16513103 DOI: 10.1016/j.cca.2006.01.020]

103 **Khan F**, Ali R. Antibodies against nitric oxide damaged poly L-tyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. *J Biochem Mol Biol* 2006; **39**: 189-196 [PMID: 16584635 DOI: 10.5483/BMBRep.2006.39.2.189]

104 **Dixit K**, Khan MA, Sharma YD, Moinuddin K. Peroxynitrite-induced modification of H2A histone presents epitopes which are strongly bound by human anti-DNA autoantibodies: role of peroxynitrite-modified-H2A in SLE induction and progression. *Hum Immunol* 2011; **72**: 219-225 [PMID: 21182886 DOI: 10.1016/j.humimm.2010.12.004]

105 **Ahsan H**. 3-Nitrotyrosine: A biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions. *Hum Immunol* 2013; **74**: 1392-1399 [PMID: 23777924 DOI: 10.1016/j.humimm.2013.06.009]

106 **Gilkeson G**, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. *J Rheumatol* 1999; **26**: 318-324 [PMID: 9972965]

107 **Oates JC**, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. *Proc Assoc Am Physicians* 1999; **111**: 611-621 [PMID: 10591091 DOI: 10.1046/j.1525-1381.1999.99110.x]

108 **Rochette L**, Zeller M, Cottin Y, Vergely C. Diabetes, oxidative stress and therapeutic strategies. *Biochim Biophys Acta* 2014; **1840**: 2709-2729 [PMID: 24905298 DOI: 10.1016/j.bbagen.2014.05.017]

109 **Giacco F**, Brownlee M. Oxidative stress and diabetic complications. *Circ Res* 2010; **107**: 1058-1070 [PMID: 21030723 DOI: 10.1161/CIRCRESAHA.110.223545]

110 **Jay D**, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. *Free Radic Biol Med* 2006; **40**: 183-192 [PMID: 16413400 DOI: 10.1016/j.freeradbiomed.2005.06.018]

111 **Szabó C**, Zanchi A, Komjáti K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A. Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. *Circulation* 2002; **106**: 2680-2686 [PMID: 12438293 DOI: 10.1161/01.CIR.0000038365.78031.9C]

112 **Hoeldtke RD**, Bryner KD, McNeill DR, Hobbs GR, Baylis C. Peroxynitrite versus nitric oxide in early diabetes. *Am J Hypertens* 2003; **16**: 761-766 [PMID: 12944035 DOI: 10.1016/S0895-7061(03)00976-2]

113 **Stadler K**. Peroxynitrite-driven mechanisms in diabetes and insulin resistance - the latest advances. *Curr Med Chem* 2011; **18**: 280-290 [PMID: 21110800 DOI: 10.2174/092986711794088317]

114 **Ihnat MA**, Thorpe JE, Ceriello A. Hypothesis: the 'metabolic memory', the new challenge of diabetes. *Diabet Med* 2007; **24**: 582-586 [PMID: 17490424 DOI: 10.1111/j.1464-5491.2007.02138.x]

115 **Wang Y**, Feng W, Xue W, Tan Y, Hein DW, Li XK, Cai L. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. *Diabetes* 2009; **58**: 1391-1402 [PMID: 19324938 DOI: 10.2337/db08-1697]

116 **Cong W**, Zhao T, Zhu Z, Huang B, Ma W, Wang Y, Tan Y, Chakrabarti S, Li X, Jin L, Cai L. Metallothionein prevents cardiac pathological changes in diabetes by modulating nitration and inactivation of cardiac ATP synthase. *J Nutr Biochem* 2014; **25**: 463-474 [PMID: 24629910 DOI: 10.1016/j.jnutbio.2013.12.007]

117 **He X**, Kan H, Cai L, Ma Q. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. *J Mol Cell Cardiol* 2009; **46**: 47-58 [PMID: 19007787 DOI: 10.1016/j.yjmcc.2008.10.007]

118 **Li B**, Liu S, Miao L, Cai L. Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. *Exp Diabetes Res* 2012; **2012**: 216512 [PMID: 22645602]

119 **Stavniichuk R**, Shevalye H, Lupachyk S, Obrosov A, Groves JT, Obrosova IG, Yorek MA. Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. *Diabetes Metab Res Rev* 2014; **30**: 669-678 [PMID: 24687457 DOI: 10.1002/dmrr.2549]

120 **Obrosova IG**, Mabley JG, Zsengellér Z, Charniauskaya T, Abatan OI, Groves JT, Szabó C. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. *FASEB J* 2005; **19**: 401-403 [PMID: 15611153]

121 **Yorek MA**. The role of oxidative stress in diabetic vascular and neural disease. *Free Radic Res* 2003; **37**: 471-480 [PMID: 12797466 DOI: 10.1080/1071576031000083161]

122 **Drel VR**, Mashtalir N, Ilnytska O, Shin J, Li F, Lyzogubov VV, Obrosova IG. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. *Diabetes* 2006; **55**: 3335-3343 [PMID: 17130477 DOI: 10.2337/db06-0885]

123 **Zettl UK**, Mix E, Zielasek J, Stangel M, Hartung HP, Gold R. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. *Cell Immunol* 1997; **178**: 1-8 [PMID: 9184692 DOI: 10.1006/cimm.1997.1113]

124 **Mitrovic B**, Ignarro LJ, Vinters HV, Akers MA, Schmid I, Uittenbogaart C, Merrill JE. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. *Neuroscience* 1995; **65**: 531-539 [PMID: 7777166 DOI: 10.1016/0306-4522(94)00491-M]

125 **Cross AH**, Manning PT, Stern MK, Misko TP. Evidence for the production of peroxynitrite in inflammatory CNS demyelination. *J Neuroimmunol* 1997; **80**: 121-130 [PMID: 9413267 DOI: 10.1016/S0165-5728(97)00145-8]

126 **Smith KJ**, Lassmann H. The role of nitric oxide in multiple sclerosis. *Lancet Neurol* 2002; **1**: 232-241 [PMID: 12849456 DOI: 10.1016/S1474-4422(02)00102-3]

127 **Maeda H**, Okamoto T, Akaike T. Human matrix metalloprotease activation by insults of bacterial infection involving proteases and free radicals. *Biol Chem* 1998; **379**: 193-200 [PMID: 9524071 DOI: 10.1515/bchm.1998.379.2.193]

128 **Redford EJ**, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. *Brain* 1997; **120** (Pt 12): 2149-2157 [PMID: 9448570 DOI: 10.1093/brain/120.12.2149]

129 **Aboul-Enein F**, Weiser P, Höftberger R, Lassmann H, Bradl M. Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis. *Acta Neuropathol* 2006; **111**: 539-547 [PMID: 16718350 DOI: 10.1007/s00401-006-0047-y]

130 **Petković F**, Blaževski J, Momčilović M, Mostarica Stojkovic M, Miljković D. Nitric oxide inhibits CXCL12 expression in neuroinflammation. *Immunol Cell Biol* 2013; **91**: 427-434 [PMID: 23732617 DOI: 10.1038/icb.2013.23]

131 **Boughton-Smith NK**. Pathological and therapeutic implications for nitric oxide in inflammatory bowel disease. *J R Soc Med* 1994; **87**: 312-314 [PMID: 7519268]

132 **Middleton SJ**, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. *Lancet* 1993; **341**: 465-466 [PMID: 8094492 DOI: 10.1016/0140-6736(93)90211-X]

133 **Ribbons KA**, Zhang XJ, Thompson JH, Greenberg SS, Moore WM, Kornmeier CM, Currie MG, Lerche N, Blanchard J, Clark DA. Potential role of nitric oxide in a model of chronic colitis in rhesus macaques. *Gastroenterology* 1995; **108**: 705-711 [PMID: 7533111 DOI: 10.1016/0016-5085(95)90442-5]

134 **Middleton SJ**, Shorthouse M, Hunter JO. Relaxation of distal colonic circular smooth muscle by nitric oxide derived from human leucocytes. *Gut* 1993; **34**: 814-817 [PMID: 8314515 DOI: 10.1136/gut.34.6.814]

135 **Balkwill F**, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; **357**: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)04046-0]

136 **Sica A**, Porta C, Morlacchi S, Banfi S, Strauss L, Rimoldi M, Totaro MG, Riboldi E. Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). *Cancer Microenviron* 2012; **5**: 133-149 [PMID: 21948460 DOI: 10.1007/s12307-011-0091-6]

137 **Porta C**, Riboldi E, Sica A. Mechanisms linking pathogens-associated inflammation and cancer. *Cancer Lett* 2011; **305**: 250-262 [PMID: 21093147 DOI: 10.1016/j.canlet.2010.10.012]

138 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

139 **Hanahan D**, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell* 2012; **21**: 309-322 [PMID: 22439926 DOI: 10.1016/j.ccr.2012.02.022]

140 **Sica A**, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. *J Clin Invest* 2007; **117**: 1155-1166 [PMID: 17476345 DOI: 10.1172/JCI31422]

141 **Solinas G**, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. *J Leukoc Biol* 2009; **86**: 1065-1073 [PMID: 19741157 DOI: 10.1189/jlb.0609385]

142 **Molon B**, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarato L, Fruttero R, Gasco A, Bronte V, Viola A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *J Exp Med* 2011; **208**: 1949-1962 [PMID: 21930770 DOI: 10.1084/jem.20101956]

143 **Thomsen LL**, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. *Br J Cancer* 1995; **72**: 41-44 [PMID: 7541238 DOI: 10.1038/bjc.1995.274]

144 **Reveneau S**, Arnould L, Jolimoy G, Hilpert S, Lejeune P, Saint-Giorgio V, Belichard C, Jeannin JF. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. *Lab Invest* 1999; **79**: 1215-1225 [PMID: 10532585]

145 **Zhang Y**, He N, Zhou J, Chen Y. The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma. *Clin Imaging* 2011; **35**: 165-173 [PMID: 21513851 DOI: 10.1016/j.clinimag.2010.06.002]

146 **Fukumura D**, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. *Nat Rev Cancer* 2006; **6**: 521-534 [PMID: 16794635 DOI: 10.1038/nrc1910]

147 **Weigert A**, Brüne B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. *Nitric Oxide* 2008; **19**: 95-102 [PMID: 18486631 DOI: 10.1016/j.niox.2008.04.021]

148 **Jeannin JF**, Leon L, Cortier M, Sassi N, Paul C, Bettaieb A. Nitric oxide-induced resistance or sensitization to death in tumor cells. *Nitric Oxide* 2008; **19**: 158-163 [PMID: 18495079 DOI: 10.1016/j.niox.2008.04.024]

149 **Leon L**, Jeannin JF, Bettaieb A. Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis. *Nitric Oxide* 2008; **19**: 77-83 [PMID: 18474258 DOI: 10.1016/j.niox.2008.04.014]

150 **Lechner M**, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. *Semin Cancer Biol* 2005; **15**: 277-289 [PMID: 15914026 DOI: 10.1016/j.semcancer.2005.04.004]

151 **Jones LE**, Ying L, Hofseth AB, Jelezcova E, Sobol RW, Ambs S, Harris CC, Espey MG, Hofseth LJ, Wyatt MD. Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. *Carcinogenesis* 2009; **30**: 2123-2129 [PMID: 19864471 DOI: 10.1093/carcin/bgp256]

152 **Norbury CJ**, Zhivotovsky B. DNA damage-induced apoptosis. *Oncogene* 2004; **23**: 2797-2808 [PMID: 15077143 DOI: 10.1038/sj.onc.1207532]

153 **Dimmeler S**, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. *J Exp Med* 1997; **185**: 601-607 [PMID: 9034139 DOI: 10.1084/jem.185.4.601]

154 **Török NJ**, Higuchi H, Bronk S, Gores GJ. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. *Cancer Res* 2002; **62**: 1648-1653 [PMID: 11912135]

155 **Muntané J**, De la Rosa AJ, Marín LM, Padillo FJ. Nitric oxide and cell death in liver cancer cells. *Mitochondrion* 2013; **13**: 257-262 [PMID: 23009756 DOI: 10.1016/j.mito.2012.09.004]

156 **Chao JI**, Kuo PC. Role of p53 and p38 MAP kinase in nitric oxide-induced G2/M arrest and apoptosis in the human lung carcinoma cells. *Carcinogenesis* 2004; **25**: 645 [PMID: 15037523 DOI: 10.1093/carcin/bgh127]

157 **Garbán HJ**, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. *J Immunol* 2001; **167**: 75-81 [PMID: 11418634 DOI: 10.4049/jimmunol.167.1.75]

158 **Lahdenranta J**, Hagendoorn J, Padera TP, Hoshida T, Nelson G, Kashiwagi S, Jain RK, Fukumura D. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. *Cancer Res* 2009; **69**: 2801-2808 [PMID: 19318557 DOI: 10.1158/0008-5472.CAN-08-4051]

159 **Massi D**, De Nisi MC, Franchi A, Mourmouras V, Baroni G, Panelos J, Santucci M, Miracco C. Inducible nitric oxide synthase expression in melanoma: implications in lymphangiogenesis. *Mod Pathol* 2009; **22**: 21-30 [PMID: 18660796 DOI: 10.1038/modpathol.2008.128]

160 **Franchi A**, Massi D, Santucci M, Masini E, Rossi Degl'Innocenti D, Magnelli L, Fanti E, Naldini A, Ardinghi C, Carraro F, Gallo O. Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. *J Pathol* 2006; **208**: 439-445 [PMID: 16278821 DOI: 10.1002/path.1892]

161 **Mehta P**. Potential role of platelets in the pathogenesis of tumor metastasis. *Blood* 1984; **63**: 55-63 [PMID: 6360248]

162 **Bingisser RM**, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. *J Immunol* 1998; **160**: 5729-5734 [PMID: 9637481]

163 **Macphail SE**, Gibney CA, Brooks BM, Booth CG, Flanagan BF, Coleman JW. Nitric oxide regulation of human peripheral blood mononuclear cells: critical time dependence and selectivity for cytokine versus chemokine expression. *J Immunol* 2003; **171**: 4809-4815 [PMID: 14568959 DOI: 10.4049/jimmunol.171.9.4809]

164 **Dave B**, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P, Yu KD, Shao Z, Li X, Gilcrease M, Lai Z, Chen Y, Huang TH, Shen H, Liu X, Ferrari M, Zhan M, Wong ST, Kumaraswami M, Mittal V, Chen X, Gross SS, Chang JC. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. *Proc Natl Acad Sci USA* 2014; **111**: 8838-8843 [PMID: 24876273 DOI: 10.1073/pnas.1320769111]

165 **Godoy LC**, Anderson CT, Chowdhury R, Trudel LJ, Wogan GN. Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin. *Proc Natl Acad Sci USA* 2012; **109**: 20373-20378 [PMID: 23185001 DOI: 10.1073/pnas.1218938109]

166 **Lampson BL**, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB, Cardona DM, Counter CM. Targeting eNOS in pancreatic cancer. *Cancer Res* 2012; **72**: 4472-4482 [PMID: 22738914 DOI: 10.1158/0008-5472.CAN-12-0057]

**P-Reviewer:** Wu S **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Nitric oxide in immune cells**

|  |  |  |
| --- | --- | --- |
| Cell compartment | Features | Ref. |
| Innate immunity |  |  |
| Macrophage | | |
| M1 | High level of NO  Expression of iNOS  NO-mediated cytotoxicity | [[55-59](#_ENREF_55),[61](#_ENREF_61)] |
| M2 | Reduced level of NO  Immune suppressive function |
| Natural Killer cells | | |
|  | NO-mediated cytotoxicity | [[84](#_ENREF_84),[85](#_ENREF_85)] |
|  | NO-mediated cell fitness |
| Mast cells | | |
|  | NOS expression | [[87](#_ENREF_87),[89-91](#_ENREF_89),[93](#_ENREF_93)] |
|  | NO-mediated cell adhesion and function |
| Myeloid-derived suppressor cell | | |
|  | iNOS expression  Immune modulating function | [[62](#_ENREF_62),[64](#_ENREF_64),[94](#_ENREF_94),[95](#_ENREF_95)] |
| Dendritic cells | | |
|  | NOS expression  Pathogen clearance | [[72](#_ENREF_72),[73](#_ENREF_73),[75-77](#_ENREF_75)] |
|  |  |  |
| Adaptive immunity |  |  |
| Lymphocyte | | |
| T-cell | T-cell activation and function  T-cell commitment | [[64-68](#_ENREF_64),[72](#_ENREF_72),[73](#_ENREF_73)] |
| B-cell | Reduced level of NO  T-independent antibody response | [[69](#_ENREF_69)] |

NO: Nitric oxide; NOS: Nitric oxide synthase.

**Table 2 Nitric oxide and its effect in pathologies**

|  |  |  |
| --- | --- | --- |
| Disease | Pathogenesis | Ref. |
| Autoimmune diseases |  |  |
|  | Appearance of neo-epitopes  Disruption of physical barriers  Amelioration of pathological status | [[29](#_ENREF_29),[30](#_ENREF_30),[96-98](#_ENREF_96),[101](#_ENREF_101),[123](#_ENREF_123),[126](#_ENREF_126),[130](#_ENREF_130)] |
| Metabolic disease | | |
|  | Deregulated accumulation of proteins or their abnormal modification | [[109](#_ENREF_109),[110](#_ENREF_110),[115](#_ENREF_115),[119](#_ENREF_119),[120](#_ENREF_120)] |
| Cancer | | |
|  | Establishment of an immune suppressive environment  Alteration in DNA repair mechanisms | [[140-142](#_ENREF_140),[147](#_ENREF_147),[151](#_ENREF_151),[152](#_ENREF_152),[155](#_ENREF_155),[157](#_ENREF_157),[160](#_ENREF_160)] |



**Figure 1 The distinctive effects of nitric oxide in immune cell subsets.** Nitric oxide (NO) represents one of the key players involved in immunity and inflammation. The figure depicts the distinctive effects of NO within immune system, recapitulating its controversial behaviour. Low levels (left) could either favour Th1 response or immunoregulatory environment, while high levels (right) are either necessary for M1 macrophage effector function or could impair T cell activation. This opposite behaviour is more evident where NO concentration is poorly defined (middle), where NO sources and effects are more debated. Question marks tag open issues in the field. → or ┤ point out the effects of NO directly produced by the indicated cell on different targets. ← or ├ point out the effects of NO originated by different (not specifically indicated) sources on different targets.